Welcome to our dedicated page for EBR SYS SEC filings (Ticker: EBRCZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EBR Systems, Inc. filings document an emerging growth company’s financial updates, governance votes, and capital-structure changes. The company’s Form 8-K reports include preliminary operating results, commercial and clinical progress, annual and special meeting voting results, and amendments to its certificate of incorporation.
Proxy materials for EBRCZ describe director elections, equity plan matters, shareholder approvals, common stock proposals, CHESS Depositary Interests, and related governance procedures. The filing record also documents the company’s reverse stock split, security issuance ratifications, and recurring disclosure controls around unaudited preliminary financial information.
EBR Systems, Inc. reported its first meaningful commercial quarter, with Q1 2026 revenue of $2.4M from WiSE CRT System implants but a net loss of $17.1M and a gross margin of 7.8%. The company completed 41 commercial implants across 19 U.S. hospitals.
Cash, cash equivalents and marketable securities totaled $30.9M as of March 31, 2026, against noncurrent debt of $41.8M and negative operating cash flow of $20.3M for the quarter. Management discloses “substantial doubt” about EBR’s ability to continue as a going concern without raising additional capital.
Operating expenses rose sharply as EBR scaled commercialization, with research and development at $6.4M and selling, general and administrative expenses at $9.9M. Adjusted EBITDA was a loss of $15.1M, underscoring the need to grow procedure volumes or secure new funding to support ongoing operations and service upcoming debt maturities.
EBR Systems, Inc. director Will Allan R received a grant of stock options to buy 42,106 shares of common stock. The options have an exercise price of $3.7999 per share and expire on May 5, 2036. Following this award, he holds derivative rights over 42,106 underlying shares.
According to the vesting terms, 1/12 of the options will vest on June 6, 2026, with additional portions vesting monthly thereafter, as long as he continues as a service provider through each vesting date.
EBR Systems, Inc. director David Steinhaus received a grant of stock options covering 34,211 shares of common stock. The options have an exercise price of $3.7999 per share and expire on May 5, 2036. One-twelfth of the options will vest on June 6, 2026 and then monthly, as long as he continues as a service provider.
EBR Systems, Inc. director Christopher Nave received a grant of stock options covering 34,211 shares of common stock. The options have an exercise price of $3.7999 per share and expire on May 5, 2036.
Vesting is monthly, with 1/12 of the option shares vesting on June 6, 2026 and each month thereafter, as long as he continues as a service provider. After this grant, he holds 34,211 derivative securities directly from this award.
EBR Systems, Inc. director Trevor J. Moody received a grant of stock options covering 34,211 shares of Common Stock. The options have an exercise price of $3.7999 per share and expire on May 5, 2036.
All 34,211 underlying shares are scheduled to vest in equal monthly installments, with 1/12 of the option vesting on June 6, 2026 and on each month thereafter, as long as Moody continues as a service provider. Following this grant, he holds 34,211 derivative securities directly related to these options.
EBR Systems, Inc. President and CEO John McCutcheon received a grant of stock options covering 188,462 shares of Common Stock. The options have an exercise price of $3.7999 per share and expire on May 5, 2036.
According to the vesting terms, 1/48 of the option shares will vest on June 6, 2026, with additional portions vesting monthly thereafter, as long as he continues as a service provider. Following this grant, he directly holds options for 188,462 shares.
EBR Systems, Inc. director Bronwyn Evans received a grant of stock options covering 34,211 shares of common stock. The options have an exercise price of $3.7999 per share and expire on May 5, 2036. One-twelfth of the options will vest on June 6, 2026 and monthly thereafter, as long as Evans continues as a service provider.
EBR Systems director Karen Drexler received a new stock option grant. She was awarded options to acquire 34,211 shares of Common Stock at an exercise price of $3.7999 per share. All 34,211 options are held directly following this grant.
According to the vesting terms, 1/12 of the shares subject to the option will vest on June 6, 2026, and an additional 1/12 will vest each month thereafter, as long as she continues as a service provider. The options are scheduled to expire on May 5, 2036 if not exercised.
EBR Systems, Inc. reported the results of its 2026 annual stockholder meeting held via webcast. Stockholders elected Class II directors John McCutcheon and Bronwyn Evans to serve until the 2029 annual meeting.
They also approved adding 18,010,366 shares of common stock to the 2021 Equity Incentive Plan under its evergreen provision and ratified multiple option grants to directors and related entities. These grants include options valued at US$716,154 for John McCutcheon, US$160,000 for Allan Will, and several US$130,000 awards for other directors and their nominated entities, all under Australian Securities Exchange listing rules.
EBR Systems, Inc. furnished an update highlighting strong early commercial adoption of its WiSE wireless cardiac pacing system and preliminary Q1 2026 results. The company completed its 71st commercial implant, including 41 commercial patients in Q1 2026, more than double the prior quarter’s case count.
During Q1 2026, EBR signed 16 additional purchase agreements with target centres, bringing the total to 37, and expanded its implanter base to 55 trained physicians, with 22 trained in the quarter. The company also implemented a 1-for-10 reverse stock split of its common stock effective April 1, 2026, while changing its CDI conversion ratio to 10:1 without altering individual ownership ratios.
Management will discuss these commercial and clinical developments, along with preliminary unaudited Q1 2026 financial information, on an investor webinar scheduled for April 10, 2026 at 09:00am AEST. All financial figures remain preliminary and unaudited pending completion of the quarter-end close and review procedures.